Literature DB >> 3500228

Enhancement of in vivo immune response by tumor necrosis factor.

P Ghiara1, D Boraschi, L Nencioni, P Ghezzi, A Tagliabue.   

Abstract

Interleukin 1 (IL-1) has been shown to regulate several immunologic functions. Since tumor necrosis factor (TNF) shares many biologic properties with IL-1, we have investigated here the role of TNF in the modulation of the immune response. We have thus tested low doses of human recombinant TNF-alpha (hu rTNF-alpha) for its capacity to enhance the in vivo antibody responses evaluated at the cellular level in the hemolytic plaque assay. It was found that hu rTNF-alpha, like human IL-1 beta, is able to enhance the immune response to a T cell-dependent antigen (sheep red blood cells). Interestingly, at variance with human recombinant IL-1 beta, hu rTNF-alpha was not able to enhance the in vivo antibody response to a T cell-independent antigen (type III pneumococcal polysaccharide). These results suggest that low levels of TNF may have a role in the modulation of the immune response in vivo and shed new light on the biologic significance of this mediator.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500228

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Keratinocyte-derived tumor necrosis factor and the physiopathology of the skin.

Authors:  P F Piguet
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Antigen presenting cells.

Authors:  D L Hamilos
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 3.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 4.  Tumor necrosis factor regulation of major histocompatibility complex gene expression.

Authors:  D R Johnson; J S Pober
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation.

Authors:  M Müller; H P Eugster; M Le Hir; A Shakhov; F Di Padova; C Maurer; V F Quesniaux; B Ryffel
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

Review 6.  Tumor necrosis factor: an update on basic research and clinical applications.

Authors:  M Schleuning; R Munker
Journal:  Klin Wochenschr       Date:  1990-09-03

7.  Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11.

Authors:  T G Yin; P Schendel; Y C Yang
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

8.  An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes.

Authors:  M A Degli-Esposti; A Andreas; F T Christiansen; B Schalke; E Albert; R L Dawkins
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

9.  Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes.

Authors:  P H Hart; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

10.  Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.

Authors:  K Benihoud; I Saggio; P Opolon; B Salone; F Amiot; E Connault; C Chianale; F Dautry; P Yeh; M Perricaudet
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.